
DSM Opens New Biopharmaceutical Manufacturing Facility in Australia
DSM Pharmaceutical Products opens a cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.
The Brisbane facility offers cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing.
DSM Biologics, the business unit of DSM Pharmaceutical Products that operates the Brisbane facility, also offers process development and cGMP manufacturing in Groningen, The Netherlands. DSM previously announced contracts for the Brisbane site with DecImmune Therapeutics of Cambridge, Massachusetts, Recepta Biopharma of São Paulo, Brazil, Paranta Biosciences of Melbourne, Australia, and Opthea of Melbourne, Australia. The Brisbane facility has an output capability of 500 kg and has expansion space available for further capacity utilization.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.